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Dendritic cell (DC) immunotherapy has shown a promising ability to promote anti-tumor immunity in vitro and in vivo.
Many trials have tested single epitopes and single antigens to activate single T cell specificities, and often CD8
+ T cells
only. We previously found that determinant spreading and breadth of antitumor immunity correlates with improved
clinical response. Therefore, to promote activation and expansion of polyclonal, multiple antigen-specific CD8
+ T cells, as
well as provide cognate help from antigen-specific CD4
+ T cells, we have created an adenovirus encoding three full
length melanoma tumor antigens (tyrosinase, MART-1 and MAGE-A6, “AdVTMM”). We previously showed that adenovirus
(AdV)-mediated antigen engineering of human DC is superior to peptide pulsing for T cell activation, and has positive
biological effects on the DC, allowing for efficient activation of not only antigen-specific CD8
+ and CD4
+ T cells, but also
NK cells. Here we describe the cloning and testing of “AdVTMM2,” an E1/E3-deleted AdV encoding the three melanoma
antigens. This novel three-antigen virus expresses mRNA and protein for all antigens, and AdVTMM-transduced DC
activate both CD8
+ and CD4
+ T cells which recognize melanoma tumor cells more efficiently than single antigen AdV.
Addition of physiological levels of interferon-a (IFNa) further amplifies melanoma antigen-specific T cell activation. NK
cells are also activated, and show cytotoxic activity. Vaccination with multi-antigen engineered DC may provide for
superior adaptive and innate immunity and ultimately, improved antitumor responses.
Introduction
There are 70,230 new cases of invasive melanoma and 8,790 deaths
from melanoma in the US estimated for 2011 (www.cancer.org).
The incidence of melanoma has risen dramatically in the last several
decades, 6% annually through the 1970s and it is now 3% per year.
Recent clinical studies have demonstrated that immunotherapy
can significantly impact this disease.
1,2 Our focus has been on
immunization with well-characterized shared antigens, which we
and others have found can lead to complete objective clinical
responses in a minority of patients in Phase I/II clinical trials,
3-8 and
which allow for careful immunological analysis of tumor responses.
DC are the key physiological stimulators of naïve and primed
cells.
9-11 We demonstrated successful genetic engineering of DC
with recombinant adenovirus (AdV/DC), and its superiority to
traditional physical methods of transfection, such as CaPO4 and
lipids.
12 Tumor antigen-engineered DC are capable of processing
and presenting peptide epitopes in the context of both MHC
Class I and II
13-15 for at least ten days, while peptide-pulsed DC
present at 50% maximal level by day 2 post-pulsing.
16 Many
comparisons of exogenous peptide pulsing and tumor antigen
transfection have been performed, supporting the superiority of
DC transfection with full length tumor antigen genes for optimal
T-cell activation.
17-20 We have found broad and potent activation
of multiple CD8
+ T-cell specificities by AdV/ DC
21 as well as
strong type 1 cytokine production by CD4
+ T cells activated by
AdV/DC.
22 DC-based genetic immunotherapy strategies have
been characterized in several preclinical models systems
23-30 and
some have been tested clinically.
31-34
AdV transduction also has a positive biological impact on
human DC function. AdV/DC become more mature phenoty-
pically (increased CD83, CD86, HLA-DR) and have decreased
secretion of IL-10 and increased IL-12p70.
35-37 AdV transduction
has also been shown to result in increased expression of IFNa,
*Correspondence to: Lisa H. Butterfield; Email: butterfieldl@upmc.edu
Submitted: 10/05/11; Revised: 10/28/11; Accepted: 11/02/11
http://dx.doi.org/10.4161/onci.18628
RESEARCH PAPER
OncoImmunology 1:3, 287–297; May/June 2012; G 2012 Landes Bioscience
www.landesbioscience.com OncoImmunology 287IFNβ, IFNc, IL-1β, TNF, IL-8, IL-15 and IL-6 by DC
37,38 as
well as antigen processing machinery components TAP-1, TAP-2
and ERp57.
37 More recently, we have found that AdV/DC can
secrete a number of chemokines, including CXCL8 (IL-8) and
CXCL10 (IP-10), which promote NK cell migration
39 and
subsequent activation of both CD56
high and CD56
low/CD16
high
subsets of NK cells via transmembrane TNF and trans-presented
IL-15.
40 In the first clinical trial in which AdV/DC were
administered to melanoma patients (GM-CSF+IL-4 DC trans-
duced with both AdVMART-1 and AdVgp100), one of 17
evaluable patients had a complete response.
32 We tested an
AdVMART-1/DC vaccine in a Phase I/II trial with metastatic
melanoma patients. These DC stimulated MART-1 specific
CD8
+ and CD4
+ Type 1 T-cell responses, induced clinical
responses, and also induced NK cell activation in vivo.
41
In order to increase the immunologic strength of DC-based
vaccines, we have investigated several potential improvements:
(1) engineering the DC with multiple defined tumor antigens to
activate more diverse CD8
+ T-cell clones; (2) providing broad
cognate CD4
+ T cell help; (3) using a maturation cocktail for
DC which functions well with AdV transduction; (4) activating
innate immunity (NK cell) and (5) further boosting DC-primed
immunity with IFNa. Here, we present the preclinical data
supporting this novel approach for AdVTMM2/DC-based
immunotherapy of melanoma.
Results
AdVTMM1: Cloning and testing. To promote broad immunity
to multiple, defined antigens, we created a single adenovirus
encoding three full length melanoma antigens which include
multiple MHC class I and II epitopes. We initially subcloned the
individual cDNAs into a single CMV-driven expression cassette,
in which the three cDNAs were separated by two iterations of an
IRES sequence. This configuration of three cDNAs was shown to
be superior to related configurations.
42 The cassette was cloned
into the AdV shuttle plasmid and sequenced to confirm the
integrity of the transgenes (data not shown). This shuttle plasmid
was then recombined into a virus and a seed amplification of
AdVTMM1 was produced (Fig.S1). This seed virus was purified,
titered and tested for RNA and protein production from each of
the antigen cDNAs in the cassette. RT-PCR and protein gel
blotting demonstrated that the expected mRNAs and proteins
were produced (data not shown).
AdVTMM1 T cell responses. We tested AdVTMM1 trans-
duced DC for the ability to activate CD8
+ and CD4
+ T cells
specific to all three of these antigens. This was tested in blood
from healthy donors. Both CD8
+ and CD4
+ T cells expanded to
each antigen as demonstrated by recognition of targets pulsed
with immunodominant HLA-A2.1-restricted or HLA-DR4-
restricted peptide epitopes (Fig.1A; Table S1). T cells specific
to AdV hexon peptides were also detected, particularly among
CD4
+ T cells. These data indicate that expression of three dif-
ferent antigens in DC did not lead to interference, or dominance
of any particular antigen, as no antigens were immunodominant
among the healthy donors tested for responses. Importantly, these
polyclonal, melanoma antigen-specific T cells also recognized
antigen expressing, HLA-matched Mel526 melanoma cells. The
melanoma-specific cells in AdVTMM1/DC-stimulated cultures
were at a frequency higher than that achieved by single antigen
vector-transduced DC (Fig.1B). HLA-A2
+/HLA-DR4
+ donors
expanded both CD8
+ and CD4
+ T cells which recognized the
HLA-A2
+/HLA-DR4
+ melanoma cells, indicating that these Th1
CD4+ T cells also contribute to melanoma-specific cytokine
production.
Systemic administration of IFNa is an approved adjuvant
treatment for melanoma with pleiotropic effects on immunity.
IFNa was tested specifically because of in vivo clinical data
suggesting that high dose IFNa treatment may boost levels of
antigen-specific T cells activated by vaccines.
43 We show that the
frequency of melanoma-specific cells expanded in vitro was
further augmented by including physiological levels (1,000 U/ml)
of IFNa in the culture (Fig.1C). Any potential effect of IFNa
on the tumor cells was excluded as IFNa was only added to the
AdV/DC/T cell cultures during expansion. Together, these data
indicate that an AdV encoding three antigens can activate a higher
frequency of melanoma-specific CD8
+ and CD4
+ T cells than
single antigen AdV/DC. They also indicated that there was no
significant competition between antigens, as specific T cells to
each antigen were activated, and the presence of IFNc/IL-2
secreting AdV hexon-specific CD4
+ T cells did not preclude
melanoma recognition. Finally, that addition of IFNa allowed for
greater T cell expansion.
Instability of AdVTMM1. While testing antigen specific T cell
expansion, we performed plaque purifications on AdVTMM1 to
derive a stable clone for clinical translation. Individual plaques
derived from AdVTMM1 no longer produced three mRNAs by
RT-PCR. From viral DNA-based PCR and sequence analysis, we
found that the CMV promoter and at least part of the 5' most
cDNA (tyrosinase) were deleted, indicating that the genetic
structure was not stable. We surmised that this was most likely
due to the duplicated IRES sequences, separated by only the
350 bp MART-1 cDNA. Therefore, we recloned the virus. We
subcloned the MAGE-A6 cDNA into an RSV-driven AdV E3
region shuttle plasmid, and the tyrosinase-IRES-MART-1 cassette
was recloned together into the same CMV-driven Ad E1 region
Figure1 (See opposite page). T cell activation by AdVTMM1 transduced DC. (A) AdVTMM1/DC T cell specificity. Healthy donor T cells were activated
with AdVTMM1-transduced DC, expanding CD8
+ and CD4
+ T cells specific for each of the three encoded antigens, as tested by HLA-restricted peptides, in
the IFNc and IL-2 ELISPOT assays. (B) AdVTMM1/DC T cell recognition of antigen-expressing melanoma cells. Seven of nine individual cultures stimulated
with AdVTMM/DC recognized Mel526 by IFNc ELISPOT at a superior frequency than AdV-single antigen/DC, from three different healthy donors. Five of
the seven positive cultures are shown. (C) AdVTMM1/DC
+/2 IFNa. Five of five AdVTMM1/DC cultures testing addition of IFNa showed superior melanoma
recognition by ELISPOT, compared with AdVTMM alone. Paired cultures expanded at the same time from the same donor are shown together (B and C).
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to create AdVTMM2.
AdVTMM2 expression analysis. AdVTMM2 was tested for
both mRNA by RT-PCR and protein expression by protein gel
blot for all three antigens at multiple stages: initial lysate
(Fig. S2A), each of two rounds of plaque purification, and
subsequent large scale amplification and purification (Fig.2).
MAGE-A6 was the most difficult to clearly detect, despite using
five different antibody clones. This may be due in part to cross-
reactivity among the large and highly homologous MAGE-A gene
family members.
44 The three antigen proteins are expressed at
different levels in 293 cells, with tyrosinase at 1.2–3.1-fold higher
than MAGE-A6, and MART-1 1.1 to 2.1-fold higher than
MAGE-A6. This is expected, due to the two different promoters
used (CMV and RSV) and relative positions of the two genes in
the bicistronic cassette (tyrosinase 5' to MART-1), where the 5'
gene is often more efficiently translated.
45 In DC, the transgene
proteins can be detected by intracellular staining, with expression
levels increasing with increased MOI (Fig. S3).
AdVTMM2 T cell responses. We next stimulated T cells with
human DC transduced with AdVTMM2, to determine whether
all three antigen specificities of both CD4
+ and CD8
+ T cells
could be activated by this new viral clone. IFNc and IL-2
producing CD8
+ and CD4
+ T cells specific to peptides derived
from all three antigens were expanded, indicating successful T-cell
activation (Fig.3A and B). For CD4
+ T cell response deter-
mination, for the donors who are not HLA-DR4
+, we determine
the antigen specificity by using single antigen AdV-transduced
targets. These are compared with control AdVLacZ-transduced
targets, (the difference representing the antigen-specific response)
and untransduced targets (the large difference representing the
antigen-specific response plus the AdV virus-specific response).
An example of such data are shown in Figure3C, in which CD4
+
T cells were expanded to each of the encoded antigens. As
with AdVTMM1, with AdVTMM2 we have not observed any
evidence for antigen immunodominance, despite the relative
differences in protein expression level in transduced cells. Among
the four donors tested with AdVTMM2 in vitro, we successfully
expanded CD8
+ or CD4
+ T cell responses to all three antigens in
all 4 donors. CD8
+ and CD4
+ T cells producing IFNc were most
common, followed by IL-2-producing CD4
+ T cells. Multiplex
analysis of cell culture supernatants identified CXCL10 (IP-10)
and CXCL8 (IL-8) as the highest concentration analytes.
We detected lesser amounts of IFNc and low levels of IL-10,
while IL-12p70, IFNa and VEGF were below detection (data
not shown).
Pre-maturation of AdVTMM2/DC. Fully mature DC have
been demonstrated to have superior T cell activation properties,
which is due in part to increased costimulation, increased IL-
12p70 production, and greater stability. We and others found
that AdV transduction alone partially matures DC, and previously
investigated several maturation cocktails after AdV transduc-
tion.
35,36 While DC phenotype indicated increased maturation,
the T cell stimulatory activity was not improved over AdV trans-
duction alone. We subsequently tested IFNc + LPS as a cocktail
before and after AdVLacZ transduction
37 and observed very
different DC phenotype and cytokine and chemokine production
profiles which were dependent upon the timing of maturation
relative to AdV transduction. Here, we compared AdVTMM2/
DC with IFNc + LPS pre-matured AdVTMM2 for the frequency
of antigen-specific T cell activation. Pre-maturation proved to be a
more reliable stimulus for expansion of antigen-specific T cells to
all three antigens, and resulted in at least similar or often increased
frequency of those T cells by IFNc and IL-2 ELISPOT (Fig.4).
The pre-matured AdVTMM2/DC also show increased levels of
CD80, CD86, CD83 and CCR7, as well as improved viability
compared with AdVTMM2/DC (data not shown).
NK cell activation. We have recently found that AdVLacZ/DC
activate both major subsets of NK cells via transmembrane TNF
and trans-presented IL-15.
40 AdV/DC also secrete a number of
chemokines, including CXCL8 and CXCL10, which are
chemotactic in vitro and in vivo for NK cells.
39 In addition,
circulating CD69
+ and CD25
+ NK cells were identified in
melanoma patients immunized with AdVMART-1/DC suggest-
ing an enhanced level of NK cell activation.
41 These NK-DC
interactions may prove critical to shape the adaptive immune
response. In order to confirm that this effect is not transgene-
dependant, we tested NK cells isolated from AdVTMM1/DC and
AdVTMM2/DC cultures for activation. We found that these
cultures contained activated CD25
+/CD69
+ NK cells, both
CD56
hi/CD16
- and CD56
+/CD16
+ subsets. These activated NK
cells were capable of killing the LAK target Daudi cells (Fig.5),
compared with the NK cells from the unstimulated PBMC.
Therefore, the AdVTMM/DC activate NK cells, as expected.
Figure2. The AdVTMM2 cloned virus produces
mRNA and protein for all three antigens. mRNA
expression in AdVTMM2 was tested in 293 cells
which were transduced with AdVTMM2 or left
untransduced (negative control). Antigen
expressing Mel526 cells served as a positive control
for tyrosinase and MART-1. A549 served as a positive
control for MAGE-A6. RNA was isolated and
underwent RT-PCR to detect mRNA for each
antigen. The same groups were tested for protein by
protein gel blot, with B-actin as a loading control.
Two tests with the 5B57 antibody for MAGE-A6 are
shown.
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AdVTMM2 is stable, that this virus directs expression of the
three encoded antigens, and that DC transduced with three full
length antigens can activate and expand CD8
+ and CD4
+ T cells
which produce IFNc and IL-2 upon recognition of all three
antigens. These polyclonal, multiple antigen-specific T cells
recognize antigen-expressing melanoma cells in a manner superior
to single antigen engineered DC. These effects are further
amplified by IFNa at physiologically achievable levels. These data
also support translation of this strategy to a clinical trial in which
melanoma patients are vaccinated with IFNc/LPS pre-matured
AdVTMM2/DC to promote adaptive antigen-specific CD8
+ and
CD4
+ T cell responses as well as innate NK cell activation, in
conjunction with high dose IFNa to further amplify these effects.
Discussion
In this report, we describe the preclinical development of an
adenovirus expressing three full length melanoma tumor associated
antigens and its ability to stimulate multiple antigen-specific, type 1
Figure3. AdVTMM2 transduced DC activate CD8
+ and CD4
+ T cells specific to all three antigens. Antigen specificity was tested with T cells from four
different healthy donors which were activated with AdVTMM2-transduced DC. The cultures expanded CD8
+ and CD4
+ T cells specific for each of the three
encoded antigens, as tested by HLA-A2 and DR4-restricted peptides (Table S1), in IFNc and IL-2 ELISPOTS (A and B) in five different experiments.
In the case of HLA-DR4-negative donors, total CD4
+ T cell responses to each antigen were determined by testing recognition of autologous DC
transduced with single antigen AdV and control AdVLacZ (C).
www.landesbioscience.com OncoImmunology 291Figure4. Maturation of DC prior to AdVTMM2 transduction enhances immunogenicity. AdVTMM2/DC stimulated cultures were tested with and without
DC pretreatment with IFNc + LPS. After three weekly stimulations, the total frequency of antigen-specific lymphocytes (without T cell subset purification)
producing IFNc was tested in two donors. Reactivity to autologous DC loaded with Mel526 lysate was also compared.
Figure5. AdVTMM/DC activate NK cells. Phenotype and cytotoxicity of NK cells from two different donors was tested by flow cytometry. (A) CD56
hi/CD16
-
and CD56
+/CD16
+ NK cells from unstimulated PBMC and from cultures stimulated with AdVMAGE A-6/DC, AdVTMM1/DC and AdVTMM1/DC + IFNa were
stained for surface CD25 and CD69 and intracellularly stained for granzyme B content. AdVTMM2/DC cultures also contained . 95% CD69
+ NK cells
(not shown). (B) The ability to upregulate 7-AAD on the LAK target Daudi (labeled with CTO) was compared between unstimulated NK cells and NK cells
isolated from AdVTMM2/DC cultures. Three different ratios of NK cells to Daudi targets were tested (10:1, 50:1 and 100:1).
292 OncoImmunology Volume 1 Issue 3T cells, as well as activate NK cells when used to transduce DC. The
rationale for development of this virus is based on the immuno-
logical responses of our previous melanoma immunotherapy clinical
trials in which immunization with a single MART-127–35 peptide
on DC
4,7 or an AdV encoding one full length (118aa) antigen
(MART-1)
41 all led to successful immunization of patients, with
activation and expansion of MART-1 specific T cells. However, we
observed that clinical responseand improved survivalwere correlated
with determinant spreading and antigenic breadth, indicating that
immune responses to multiple antigens is critical. This may relate to
the importance of in vivo cross-presentation after tumor lysis or
to overcoming antigen loss variants. Therefore, in order to induce
antigenically broad immune responses from the vaccine adminis-
tered, we created a virus encoding these three different antigens.
The antigens included in the AdV were chosen based on our
experience with MART-1 and data in the literature suggesting
immunogenicity and ability to induce clinical response. The
MART-1 protein has been hypothesized to be localized to the
melanosome.
46,47 For HLA-A2.1 allele, the immunodominant
peptide (MART-127–35) has been identified, although other
peptides, including MART-153–62 may be processed and pre-
sented.
48 The immunodominant MART-127–35 peptide has been
shown to bind other subtypes of the A2 superfamily (A2.2, 2.4, 2.5,
2.6, 2.9 and A69.1) with similar affinity to that of HLA-A2.
49 The
MHC class II-restricted DR4 epitope was also described.
50 This
antigen has been associated with the induction of vitiligo, a positive
prognostic factor for patients with melanoma.
4,33,51-54
Tyrosinase is also a melanoma lineage antigen, and is part of
the melanin biosynthesis pathway. It is expressed by 70% of
melanoma cell lines and almost all melanoma tumors.
55 It is
recognized by TIL infiltrating melanoma lesions and associated
with clinical response.
56 It is also associated with human
vitiligo
52,53 although that is controversial.
57,58 MAGE-A6 is a
tumor-specific “cancer-testes” antigen, part of the large family of
MAGE genes. MAGE-A6 T cells were found to be expanded in a
regressing tumor lesion, and stably expressed in patient tumor.
59
Work from the Storkus group found that Type 1 CD4
+ T-cell
responses (IFNc) to this antigen are associated with lower tumor
burden while Type 2 (IL-5) T-cell responses are associated with
high tumor burden.
60 MAGE-A genes may also play a tumor-
promoting function.
61 Lineage antigens MART-1 and tyrosinase
are expressed in .93% of tumors regardless of stage, and several
MAGE-A family members increased expression with increased
tumor stage. These data support targeting these widely expressed
shared antigens and reduces concern that they may be commonly
lost with progression.
There are other strategies for induction of multiple antigen-
specific responses. One is with synthetic peptides (which are
commonly used and inexpensive), but peptide binding affinity
and binding half-life are a concern, as well as restricting trial
enrollment to patients whose HLA alleles correspond to defined
epitopes. This is a particular concern with MHC class II alleles
which are more polymorphic and have fewer epitopes defined.
Another is loading DC with tumor-derived DNA, mRNA or
protein, however, the uncharacterized nature of these approaches
makes immune monitoring for vaccine-induced responses and
those acquired spontaneously via cross-presentation and sub-
sequent determinant spreading impossible to detect. Our con-
struct did express the antigens at different levels. This could
potentially impact T cell responses resulting from DC transduc-
tion with this virus. There are many reports indicating that
antigen must be present at a sufficiently high level for process-
ing and presentation of peptide epitopes at a level sufficient for
T-cell activation, but not at such a high level that responses are
inhibited, or develop in a tolerogenic or regulatory way.
62,63
Due to the lack of immunodominance, Type 1 immunity and
minimal IL-10 we observed, the antigen expression levels from
AdVTMM2 are within acceptable limits. One could also use
three single antigen AdV vectors for DC transduction, but the
enormous cost of GMP production and testing of each vector for
clinical use is prohibitive.
Cancer vaccines may benefit from being combined with other
immune stimulants. IFNa has pleiotropic effects on many
hematopoietic and tumor cell types. We hypothesize that systemic
delivery of IFNa may act to prolong the expansion of CD8
+
T cells activated by the vaccine,
64 as well as promote cross-
priming.
65,66 Our in vitro data (Fig.1C) supports this positive
effect. There is only one report of administration of IFNa
following genetic vaccination regimen,
43 in which four of seven
patients demonstrated increased CD8
+ T cell responses (tetramer)
specific for the previous gp100 vaccine, and two patients with
active measurable tumor exhibited objective antitumor responses.
We hypothesize that patients receiving systemic IFNa after
vaccination will have a significant boost in vaccine-stimulated
T cell responses compared with directly post-DC vaccinations.
NK cells have been demonstrated to play a critical role in
immune surveillance of cancer,
67 and their ability to cross-talk
with DC is well described.
68,69 We recently showed that AdV/DC
secrete CXCL8 and CXCL10, which recruit both major NK cell
subsets toward the AdV/DC,
39 and, that once in contact, the
AdV/DC activate NK cell Th1 functions via transmembrane
TNF and transpresented IL-15.
40 These early, innate immune
activation events may be of critical importance in shaping a strong
Th1/Tc1 adaptive immune response. Here, we confirmed that,
like AdVLacZ/DC, AdVTMM/DC are also capable of NK cell
activation and promotion of lytic function.
In summary, our data support clinical testing of AdVTMM2/
DC for broad activation of polyclonal, Type 1 CD8
+ and CD4
+
T cells, as well as NK cells, which, particularly when “boosted” by
systemic IFNa, may promote strong melanoma antitumor
immunity in vivo. This study is now planned as part of the
Melanoma and Skin Cancer Program at the University of
Pittsburgh Cancer Institute. The use of such defined antigens
allows immunologic monitoring to detect spontaneous immunity,
vaccine-stimulated immunity and determinant spreading to other
defined antigens (like gp100 or NY-ESO-1), which will shed light
on the immunologic mechanism of clinical response.
Materials and Methods
Cell lines. The human CML cell line K562 stably transfected
with HLA-A*0201 (K562/A2.1) was generously provided by
www.landesbioscience.com OncoImmunology 293Wolfgang Herr (Mainz, Germany) and the HLA-A2
+/AFP-
expressing HCC cell line HepG2 was obtained from ATCC
(HB-8065). Mel526 is a human melanoma cell line which is
HLA-A2
+/HLA-DR4
+ and which expresses MART-1/Melan-A,
tyrosinase and MAGE-A6. NK and LAK activities were tested
against K562 erythroleukemia and DAUDI lymphoma cell lines
(ATCC, CCL-243, CCL-213), respectively. The cell lines were
cultured in Advanced RPMI 1640 medium (12633-012) supple-
mented with 10% fetal bovine serum (FBS), 1% penicillin-
streptomycin (15140-163) and 1% L-glutamine (25030164, all
reagents from Invitrogen), in a humidified 37°C incubator under
5% CO2 tension.
Antibodies and flow cytometry. DC phenotype and matura-
tion were examined using fluorochrome-conjugated antibodies
against the following cell surface markers: CD80, CD83 (BD
PharMingen), HLA-A,B,C (BioLegend), HLA-DR and CD86
(Beckman Coulter). NK cell phenotype and activation were
investigated using: CD8
+, CD16, CD3 (Beckman Coulter),
CD56 and CD69 (BD PharMingen). Transgene expression was
confirmed by protein gel blot using several different primary
antibodies to MAGE-A6 [ab38495, Abcam; sc33233, sc33234
and sc20034, Santa Cruz; 5B57 (a gift from W. Storkus)],
Tyrosinase (ab55902) and MART-1 (ab3168) (Abcam), and
secondary antibodies (ab672, SC-2314 from Abcam and Santa
Cruz Biotechnology, respectively). Intracellular staining for
antigen expression in DC was performed using primary antibodies
to MAGE-A6 (Santa Cruz, 20034), Tyrosinase (Santa Cruz,
20035) and MART-1 (Santa Cruz, 20032) and PE-labeled
secondary antibody (Dako, R0480). Briefly, transduced cells
were fixed for 20 min. in 4% w/v paraformaldehyde/PBS,
washed in FACS buffer (PBS/0.2% BSA/0.02% NaN3), blocked
for 30 min. with goat serum, and permeabilized (eBioscience,
00–8333) according to manufacturer’s instructions. Cells were
analyzed using a CyAn flow cytometer (Dako) and Summitt
v.4.3 software.
Peptides. Peptides were synthesized at the University of
Pittsburgh Peptide Synthesis Facility using standard f-moc
technology. Stock solutions were prepared in DMSO
(10 mg/mL) and were kept at -80°C until use. The following
peptides were used (also shown in Table S1): HLA-A2-restricted:
MART-127–35 AAGIGILTV, Tyrosinase1–9 MLLAVLYCL,
MAGE-A6271–279 FLWGPRALV and AdV hexon711–721
TFYLNHTFKK. HLA-DR4-restricted: MART-151–73 RNG-
YRALMDKSLHVGTQCALTRR, Tyrosinase448–462 DYSYLQ-
DSDPDSFQD, MAGE-A6121–144 LLKYRAREPVTKAEM-
LGSVVGNWQ and MAGE-A6246–263 LTQYFVQENYLE-
YRQVPG and the AdV promiscuous hexon peptides: 571–600
NLLLLPGSYTYEWNFRKDVNMVLQSSLGND, 856–885
VDSITQKKFLCDRTLWRIPFSSNFMSMGAL and 901–930
LDMTFEVDPMDEPTLLYV LFEVFDVVRVHR.
Cloning of AdVTMM1 and AdVTMM2 and sequencing.
AdVTMM1 is an Ad5 E1/E3 deleted adenovirus with the cDNAs
for tyrosinase, MART-1 and MAGE-A6 cloned into a single
expression cassette, with two copies of an Internal Ribosome
Entry Site (IRES) sequence, driven by the CMV promoter and
ending in the SV40 poly A sequence, subcloned into the E1
region. The IRES sequence, obtained from pIRES (Clontech
Laboratories, Inc., 631605), is derived from the encephalomyo-
carditis virus (ECMV).
The adenoviral vector “AdVTMM2” is driven by a single CMV
promoter and a single RSV promoter, contains the same three
cDNAs (Tyrosinase, MART-1, and MAGE-A6). These cDNAs
are in two expression cassettes, one CMV-driven, with Tyrosinase
and MART-1 joined by an IRES. The second cassette is an RSV-
driven MAGE-A6 cDNA.
The shuttle vector construct was built in several sequential
subcloning steps. First, the Tyrosinase coding sequence was
subcloned from pEF6huTyros (a gift from V.H. Engelhard,
University of Virginia), into the pShuttle2 vector (Clontech
Laboratories, Inc., 631513). The sequence of this cDNA was
confirmed to match that of human Tyrosinase, GenBank acces-
sion #BC027179. The MART-1 cDNA was then sub-cloned
from pRcCMV-MART-1
29 into pIRES. The MART-1 cDNA
was confirmed to match that of human MART-1, GenBank
accession #NM_005511. The IRES-MART-1 fragment was then
ligated into pShuttleHuTyros. The Tyrosinase-IRES-MART-1
cassette was then subcloned into the Viraquest shuttle plasmid
VQAd5CMV. Lastly, the MAGE-A6 cDNA was amplified from
pBAD-Topo-MAGE-A6 (a gift from W.J. Storkus, University of
Pittsburgh
70 by PCR). The cDNA was amplified using gene-
specific primers with added SalI and NotI sites to facilitate
subcloning into pIRES. The MAGE-A6 cDNA was confirmed
to be human MAGE-A6, GenBank accession #BC067731. For
AdVTMM1, The 1639 bp fragment XhoI-IRES-MAGE6-NotI
was ligated into pShuttle2huTyr-IRES-MART1. This cassette
was subcloned into the Viraquest shuttle plasmid VQAd5CMV,
and recombined into an intial virus lysate, which underwent
mRNA and protein expression testing.
For AdVTMM2, the fragment XhoI-IRES-MAGE6-NotI was
ligated into VQAd5RSV shuttle plasmid. The VQAd5RSV-
MAGEA6 shuttle plasmid and the VQAd5CMV-Tyros.-IRES-
MART-1 shuttle plasmid were sent to Viraquest for sequential
recombination into the AdV. A lysate was sent to the Butterfield
lab to confirm mRNA and protein expression of all three
melanoma antigens. After this mRNA and protein expression
confirmation, this initial lysate construct was sequenced to con-
firm the accuracy of the insert sequences. The lysate was then
plaque purified, and all tested clones expressed all three mRNAs
(RT-PCR). One plaque was amplified and underwent a second
round of plaque purification, and tested second-round plaques
again expressed mRNA for all three antigens. Protein expression
from two plaques was tested, and one clone was selected for
amplification, purification, titering and further testing.
Virus amplification, purification and titer. Infected 293 cells
(ATCC, CRL-1573) are freeze/thawed and the cleared supernat-
ant is layered onto a CsCl step gradient (1.2 g/mL/1.4 g/mL) and
centrifuged at 35,000 rpm 1.5 h. The virus band is dialyzed
(Pierce Slide-a-lyzer 10K, Tris/MgCl2/glycerol), and concentrated
(Millipore, UFC205024PL) in formulation buffer (2.5% glycerol
(w/v), 25 mM NaCl and 20 mM TRIS-HCl, pH 8.0; Clontech),
aliquoted and titered (Adeno-X Rapid Titer Kit, Clontech,
TakaraBio, 632250).
294 OncoImmunology Volume 1 Issue 3RT-PCR. Total RNA was isolated (Qiagen Kit.; 74104, Qiagen)
and quantified by UV spectrophotometry. RT-PCR was performed
using Random Primers, 11034731001 and Superscript
TM III
Reverse Transcriptase, 18080–044, Ampli Taq Gold polymerase,
EN-387. Sequenced-specific primers were as follows:
Tyrosinase, Forward: 5'-ATT-CCA-TAT-TGG-GAC-TGG-
CGG-GAT-3'/Tyrosinase
Reverse: 5'-CAA-TGG-GTG-CAT-TGG-CTT-CTG-GAT-3'
MART-1, Forward: 5' – TGC-AGA-TAT-CCA-TCA-CAC-
TGG- 3'
MART-1, Reverse: 5' –GGA-GGG-GCA-AAC-AAC-AGA T –3'
MAGE-A6, Forward: 5'- AGT-AGG-AAG-GTG-GCC-AAG-
TTG-GTT-3'
MAGE-A6, Reverse: 5'- TAT-TGG-GTG-AGC-TTC-TTG-
GGA-3'
β-Actin, Forward: 5'-GGC-ATC-GTG-ATG-GAC-TCC-G-3'
Reverse: 5'-GCT-GGA-AGG-TGG-ACA-GCG-A-3'
All primers were prepared by Integrated DNA Technologies,
Inc. PCR reactions for β-Actin, Tyrosinase and MART-1 were 35
cycles, and for MAGE-A6, 37 cycles were used.
Protein gel blotting. Proteins were isolated in lysate buffer and
samples containing equal amounts of protein were boiled in the
loading buffer and separated by SDS-PAGE, followed by transfer
to polyvinylidene difluoride membranes. The membranes were
blocked with 5% nonfat milk for 1 h at RT, and incubated the
primary antibodies at the optimal concentrations overnight
at 4°C. After 3 washes in phosphate-buffered saline with 0.2%
Tween 20, a horseradish peroxidase-conjugated secondary
antibody was applied, and the blot was developed with enhanced
chemical reagents (Amersham Biosciences). Quantitation was
performed by scanning protein gel blot films (Epson Perfection
4490 Photo) and analyzing the band intensity (Image J 1.44 P).
The intensity for each transgene was normalized to the β-Actin
control for that sample. The data reported is averaged from five
different protein gel blot experiments.
Isolation of peripheral blood mononuclear cells (PBMC).
Peripheral blood was obtained from six different HLA-A2
+/HLA-
DR4
+/2 normal donors with their written consent, under an IRB-
approved protocol (UPCI 04-001). PBMC were separated from
blood using Ficoll-Hypaque gradient centrifugation (Cellgro;
Mediatech, Inc.). Buffy coats from healthy donors were obtained
from the Central Blood Bank (Pittsburgh, PA).
Generation of dendritic cells (DC) and DC culture. DC were
prepared as described
12 with some modifications. Mononuclear
cells (7–8  10
7) were plated in T-75 flasks (Costar, CLS430641)
in RPMI 1640/PSF/5–10% human AB serum for 2 h at 37°C in a
humidified CO2 incubator. The nonadherent cells were removed
by gentle rinsing with PBS, and the loosely-adherent cells were
cultured in medium with 800 U/mL GM-CSF (Sargramostim;
Amgen) and 500 U/mL IL-4 (Schering Plough) for 6–7 d. The
DC were harvested by vigorous washing.
Selection of CD8
+ and CD4
+ lymphocytes. Before assays,
the CD8
+ (130-045-201) and CD4
+ T cells (130-096-533)
were sequentially isolated by positive and negative MACS,
respectively with the use of immunomagnetic beads following
the manufacturer’s instructions (Miltenyi Biotech). Resulting cell
populations were . 95% CD8
+-positive according to FACS
analysis.
CTL Generation from Peptide-pulsed and AdV-transduced
DC. Peptide-specific CTL were generated as follows:
13,29 DC
were transduced with AdV at a multiplicity of infection of
1000 for 2 h at 37°C in serum-free AIM V. The DC were
centrifuged and counted, then plated in wells (1–5  10
5 DC/
well) of a 24-well plate with autologous non-adherent PBMC
in 5–10% AB serum/RPMI/antibiotics with 10 ng/mL IL-7
(Biosource, PHC0076) for 1 week, and supplemented with IL-2
(Hoffman-La Roche) at 30 U/mL every 2–4 d. After one week
culture, the nonadherent cells were counted and restimulated
with fresh transduced DC. After two restimulations, the CTL
were harvested and the CD8
+ and CD4
+ cells were isolated
and tested.
ELISPOT assays. Multiscreen HA plates (Millipore,
MAHAS4510) were coated with 4–10 ug/mL of monoclonal
Ab anti-human IFNc (1-D1K, MabTech, 3420-3) or anti-IL-2
(MabTech IL2-1, 3440-2), in PBS overnight at 4°C. After
blocking the plates with PBS/10% FBS or RPMI/10% AB
(2 h, RT), CD8
+ or CD4
+ T cells were plated at 10
5 cells/well
in duplicate wells. K562/A2.1 cells (0.5–1  10
5 well) were
pulsed with different peptides, rinsed and plated. Control wells
contained T cells (alone or with 10–100 ug/mL PHA), T cells
with unloaded APC (“no peptide”) or negative antigen pulsed
APC. Cells were removed and captured cytokine was detected
by biotinylated mAb anti-hIFNc or anti-IL-2 (MabTech, 3420-6,
3440-6) at 2 mg/mL in PBS/0.5% BSA. After washing, Avidin
Peroxidase Complex (1/100; Vectastain Elite Kit, PK-6100)
was added, and peroxidase staining was performed with 3-amino-
9-ethyl-carbazole (AEC, Sigma, AEC101) and stopped by
rinsing the plates under tap water. Spot numbers were
automatically determined with the ImmunoSpot imaging system
from Cellular Technology, Ltd. To calculate the number of
responding T cells, the mean numbers of spots with APC alone
were subtracted from mean spot numbers induced by antigen-
loaded APC.
Cell tracker orange (CTO)-based flow cytometry cytotoxicity
assay. The assay was performed as previously described with
some modification.
40 Briefly, Daudi (target cells) were labeled
with CTO. CTO
+DC and NK (effector) cells were co-incubated
at various ratios at 37°C for 3 h. Cells were stained with 7-AAD
and cytotoxicity was quantified by flow cytometry. The
percentages of cytotoxic activity was calculated using the following
equation: % specific cell death = (% 7-AAD
+CTO
+Daudi
+NK
cells - % spontaneous 7-AAD
+CTO
+Daudi)/(100-% spontaneous
7-AAD
+CTO
+Daudi)  100%.
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